Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde

Patent metadata

Field	Value
Publication number	US-10722502-B2
Application number	US-201816163942-A
Country	US
Kind code	B2
Filing date	Oct 18, 2018
Priority date	Feb 7, 2014
Publication date	Jul 28, 2020
Grant date	Jul 28, 2020

Abstract

Disclosed are crystalline free base an solvate forms of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1), such as the free base Form I, Form II and Material N. Also disclosed are crystalline free base solvates of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1).

First claim

The invention claimed is:

1. A composition comprising a crystalline ansolvate of Compound 1:

characterized by X-ray powder diffraction peaks (Cu Kα radiation) at 13.37 ° , 14.37 ° , 19.95° and 23.92 °2 θ (each ±0.2 °2θ), wherein the composition is substantially free of other ansolvate polymorphs of Compound 1.

2. The composition of claim 1 , wherein the crystalline ansolvate of Compound 1 is characterized by an X-ray powder diffraction pattern (Cu Kα radiation) substantially similar to that of FIG. 5 .

3. The composition of claim 1 , wherein the crystalline ansolvate of Compound 1 is characterized by an endothermic peak at 97 ± 2 ° C. as measured by differential scanning calorimetry.

Assignees

• Global Blood Therapeutics Inc

Inventors

• Li Zhe
• Parent Stephan D
• Houston Travis

Classifications

• C07D401/04 Primary

  directly linked by a ring-member-to-ring-member bond · CPC title

• C07B2200/13

  Crystalline forms, e.g. polymorphs · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title